• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对Knodell评分及其他组织学参数作为慢性丙型肝炎干扰素治疗反应预测指标的详细分析。

A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.

作者信息

Banner B F, Barton A L, Cable E E, Smith L, Bonkovsky H L

机构信息

Department of Pathology, University of Massachusetts Medical Center, Worcester, USA.

出版信息

Mod Pathol. 1995 Apr;8(3):232-8.

PMID:7542385
Abstract

UNLABELLED

The Knodell score is inaccurate at predicting response to interferon alpha (IFN-alpha) therapy in patients with hepatitis C. Our aim was to see if specific histologic parameters, including iron deposition in liver biopsies, are better predictors of response to IFN-alpha than the total Knodell score. Thirty-five unselected patients were studied who had hepatitis C treated with IFN-alpha between 1990 and 1993, and pretreatment serum iron indices and liver needle biopsies performed. Biopsies were divided for light microscopy and quantitative iron determination. H&E-stained slides were graded for components I, II, III, IV, and total Knodell score. Quantitative determinations were percentage of portal triads with inflammation, piecemeal necrosis, lymphoid aggregates, and inflamed bile ducts; percentage of lobules with inflammation or acidophilic bodies; and percentage of triads with positive iron stain. Complete responders (CR) to IFN-alpha were defined by normalization of serum alanine aminotransferase (< or = 40 IU/liter), and noncomplete responders (NCR) by partial or no response. Data were analyzed statistically. CR had < 40% of triads positive for iron (P = 0.02) and lower serum ferritin (P = 0.05) and higher scores for lobular necrosis (P = 0.04). The percentage of iron-positive triads correlated only with cirrhosis. Addition of cirrhosis to percentage of iron-positive triads did not improve the predictive power of the portal iron. CR and NCR did not differ with respect to total Knodell score or any of the other individual parameters except Knodell II.

CONCLUSIONS

(a) Individual features of lobular necrosis and iron staining in portal triads are better predictors of response to IFN-alpha than the total Knodell score.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

未标记

Knodell评分在预测丙型肝炎患者对干扰素α(IFN-α)治疗的反应方面并不准确。我们的目的是探讨特定的组织学参数,包括肝活检中的铁沉积,是否比Knodell总分更能预测对IFN-α的反应。对1990年至1993年间接受IFN-α治疗的35例未经挑选的丙型肝炎患者进行了研究,并进行了治疗前血清铁指标检测和肝穿刺活检。活检组织分为两部分,分别用于光学显微镜检查和铁定量测定。对苏木精-伊红(H&E)染色的切片进行I、II、III、IV组分及Knodell总分的分级。定量测定包括有炎症、桥接坏死、淋巴滤泡和炎症胆管的门管区百分比;有炎症或嗜酸性小体的小叶百分比;以及铁染色阳性的门管区百分比。IFN-α完全缓解者(CR)定义为血清丙氨酸转氨酶恢复正常(≤40 IU/L),不完全缓解者(NCR)定义为部分缓解或未缓解。对数据进行统计学分析。CR组铁染色阳性的门管区比例<40%(P = 0.02),血清铁蛋白较低(P = 0.05),小叶坏死评分较高(P = 0.04)。铁染色阳性门管区比例仅与肝硬化相关。将肝硬化因素加入铁染色阳性门管区比例并不能提高门管区铁指标的预测能力。除Knodell II外,CR组和NCR组在Knodell总分或其他任何单个参数方面均无差异。

结论

(a)小叶坏死和门管区铁染色的个体特征比Knodell总分更能预测对IFN-α的反应。(摘要截短至250字)

相似文献

1
A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.对Knodell评分及其他组织学参数作为慢性丙型肝炎干扰素治疗反应预测指标的详细分析。
Mod Pathol. 1995 Apr;8(3):232-8.
2
Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.慢性丙型肝炎干扰素治疗期间生化、病毒学及组织学反应之间的关系
Hepatology. 1997 Sep;26(3):780-5. doi: 10.1002/hep.510260335.
3
Effect of interferon therapy on bile duct inflammation in hepatitis C.
Virchows Arch. 1996 Jul;428(4-5):253-9. doi: 10.1007/BF00196698.
4
A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.
J Hepatol. 1996 Dec;25(6):833-41. doi: 10.1016/s0168-8278(96)80286-8.
5
Serum aminotransferase levels and histological disease in chronic hepatitis C.慢性丙型肝炎中的血清转氨酶水平与组织学病变
Acta Gastroenterol Belg. 1997 Jan-Mar;60(1):11-4.
6
Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.丙型肝炎病毒(HCV)RNA水平较低的慢性丙型肝炎患者的肝脏铁染色:干扰素治疗的预测标志物
Am J Gastroenterol. 1997 Sep;92(9):1463-6.
7
Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.干扰素联合熊去氧胆酸与干扰素治疗慢性丙型病毒性肝炎的比较。
Minerva Med. 1997 May;88(5):219-25.
8
Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.血清透明质酸可预测慢性丙型肝炎患者对α干扰素治疗的反应。
Hepatogastroenterology. 1995 Sep-Oct;42(5):522-7.
9
[Interferon alfa in the treatment of chronic hepatitis C: course of 24 versus 48 weeks. Results of a randomized trial].[干扰素α治疗慢性丙型肝炎:24周与48周疗程。一项随机试验的结果]
Acta Gastroenterol Latinoam. 1996;26(3):149-53.
10
Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.肝脏中铁的分布可预测慢性丙型肝炎感染对干扰素治疗的反应。
Am J Clin Pathol. 1995 Apr;103(4):419-24. doi: 10.1093/ajcp/103.4.419.

引用本文的文献

1
Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.肝内血小板活化因子及其受体增加对四氯化碳诱导的肝硬化门静脉高压的影响。
World J Gastroenterol. 2006 Feb 7;12(5):709-15. doi: 10.3748/wjg.v12.i5.709.
2
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.在丙型肝炎病毒基因1型慢性肝炎患者中,对抗病毒治疗无反应与肥胖以及细胞因子信号转导抑制因子3(SOCS-3)的肝脏表达增加有关。
Gut. 2006 Apr;55(4):529-35. doi: 10.1136/gut.2005.069674. Epub 2005 Nov 18.
3
Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.
HFE基因突变在除遗传性血色素沉着症之外的肝脏疾病中的作用。
Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):30-7. doi: 10.1007/s11894-999-0084-5.
4
Histopathology and detection of hepatitis C virus in liver.肝脏的组织病理学及丙型肝炎病毒检测
Springer Semin Immunopathol. 1997;19(1):27-45. doi: 10.1007/BF00945023.
5
High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial.
Dig Dis Sci. 1996 Jan;41(1):149-54. doi: 10.1007/BF02208597.